An observational study in Post-Operative Complications in Cardiac Surgery, sponsored by Renibus Therapeutics, Inc.. Terminated at 39 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Renibus Therapeutics, Inc. · Observational
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery:
Renibus Therapeutics, Inc. is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
All subjects who complete the Phase 3 REN-007 study are eligible to participate in the Extension Study.
Exclusion Criteria:
Patients undergoing CABG, valve, or combined CABG/valve surgery
Drug: RBT-1
Patients undergoing CABG, valve, or combined CABG/valve surgery
Drug: Placebo
Intravenous administration
Intravenous administration
Evaluation
To evaluate patient reported outcomes (PRO) using the EQ-5D questionnaire
Time frame: 12 Months Post-Cardiac Surgery
Evaluation
The number of subjects with the following clinical outcomes will be reported Clinical Outcomes: * Chronic kidney disease (CKD) - new diagnosis * Acute kidney injury (AKI) or CKD requiring dialysis * Atrial fibrillation - new-onset * Death * Myocardial infarction (MI) * Non-fatal cardiac arrest * Readmission to hospital * Reoperation for coronary artery bypass graft (CABG) and/or valve dysfunction * Stroke
Time frame: 12 Months Post-Cardiac Surgery
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renibus Therapeutics, Inc.